drug · small molecule
roxadustat
Phase 2updated 3mo agoby $KYNB KYNTRA BIO, INC.🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for chronic kidney disease and anemia (phenotype) and 4 investigational indications.
targets
Hypoxia-inducible factor prolyl hydroxylase
all catalysts(0)
nothing on the calendar yet
Trials studying roxadustat
- phase3A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
- phase4Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
- —Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
- phase1HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
- phase3Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
- phase3Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
- phase3Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
- phase3A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that